Qiagen N.V. and Oxford Immunotec Ltd. announced that they have reached a settlement in the lawsuit in the US District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to Qiagen’s QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus products.

Under terms of the agreement, all pending claims between Oxford and Qiagen and the co-defendants have been resolved. As part of the settlement, Oxford has granted Qiagen a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million. The settlement includes general releases of all parties with no admissions of wrongdoing.

This agreement does not affect Qiagen’s adjusted EPS outlook for the fourth quarter and full-year 2017 since these one-time costs are excluded from adjusted results.

Qiagen N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.